Evaluation of Prostate-Specific Antigen Glycomics Assay for the Early Detection of Prostate Cancer

Evaluation of Prostate-Specific Antigen Glycomics Assay for the Early Detection of Prostate Cancer - PSA Glyomics Assay (PGA)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49657

Enrollment

225

Registered

2020-07-03

Start date

2020-09-01

Completion date

Unknown

Last updated

2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Patients with a PSA concentration >3 ng/mL that visit the urologist for further examination.

Exclusion criteria

Exclusion criteria: Patients with a PSA concentration

Design outcomes

Primary

Measure	Time frame
The following parameters/outcomes are expected: Regarding patient information: • Study number • ID-code • Birth date • Ethnicity • Date of sample collection • Volume of prostate (echo) • PSA-concentration • Gleason score • Number of biopsies taken • Number of positive biopsies • cT-stage • Positive lymph nodes • Metastasis in the bone • Other diseases • Medication • BRCA mutation • Treatment • Prostate MRI • Cribriform growth • Family anamneses The research will provide the following outcomes: • Relative ratio of different glycoforms in urine and plasma • Normalization of glycoforms per glycosylation trait (derived trait) • The difference (delta) between urine and plasma for the found derived traits	—

Measure

Time frame

The following parameters/outcomes are expected: Regarding patient information: • Study number • ID-code • Birth date • Ethnicity • Date of sample collection • Volume of prostate (echo) • PSA-concentration • Gleason score • Number of biopsies taken • Number of positive biopsies • cT-stage • Positive lymph nodes • Metastasis in the bone • Other diseases • Medication • BRCA mutation • Treatment • Prostate MRI • Cribriform growth • Family anamneses The research will provide the following outcomes: • Relative ratio of different glycoforms in urine and plasma • Normalization of glycoforms per glycosylation trait (derived trait) • The difference (delta) between urine and plasma for the found derived traits

—

Countries

Netherlands

Outcome results